Insiders who reported open-market trades in the last 12 months at the companies Lai Wang files at. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
John Oyler - $189.61M in ONC purchases and sales in the last 12 months
Xiaodong Wang - $24.68M in ONC purchases and sales in the last 12 months
Xiaobin Wu - $8.75M in ONC purchases and sales in the last 12 months
Chan Henry Lee - $4.20M in ONC purchases and sales in the last 12 months
Lai Wang is a corporate insider, tracked as President, Global Head of R&D of BeOne Medicines Ltd. (ONC). InsiderAlpha holds 9 primary Form 4 filings for them, the earliest from 2024, updated as new SEC EDGAR filings are processed.
When did Lai Wang last file a Form 4?
The most recent primary Form 4 on record is dated 25 June 2026, one of 9 filings going back to 2024.
Has Lai Wang been buying or selling stock?
Recorded transactions: 0 open-market purchases and 12 open-market sales ($5.53M) across all tracked filings.
Lai Wang is President, Global Head of R&D of BeOne Medicines Ltd. (ONC). 9 SEC Form 4 filings on record going back to 2024, most recently on 25 June 2026. Most recent open-market trade: sold $296K of ONC on 25 June 2026. Lifetime open-market sales: $5.53M.
Recent transactions
15
The latest 15 SEC Form 4 transactions reported by Lai Wang.
InsiderAlpha's records for Lai Wang go back to 2024: 9 primary Form 4 filings, an average of 3.0 per year. 1 recorded transaction carries a Rule 10b5-1 plan flag. This identifies the marked transactions as reported under a trading plan; it does not establish the plan status of unmarked transactions.
